{"id":937797,"date":"2026-02-18T08:14:59","date_gmt":"2026-02-18T13:14:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\/"},"modified":"2026-02-18T08:14:59","modified_gmt":"2026-02-18T13:14:59","slug":"gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\/","title":{"rendered":"GSK\u2019s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwleftsingle { border-left: solid black 1pt }\n.bwlistdisc { list-style-type: disc }\n.bwpadl0 { padding-left: 0px }\n.bwrightsingle { border-right: solid black 1pt }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwtopsingle { border-top: solid black 1pt }\n.bwvertalignm { vertical-align: middle }\n.bwwidth100 { width: 100% }\n.bwwidth12 { width: 12% }\n.bwwidth7 { width: 7% }\n.bwwidth81 { width: 81% }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>GSK\u2019s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nReduction observed in RSV-related hospitalizations in adults aged \u226560 years<sup>1<\/sup><\/li>\n<li>\nAn observed reduction in major adverse cardiovascular events* in adults aged \u226560 years<sup>\u01c22<\/sup> during RSV-related hospitalization<\/p>\n<\/li>\n<li>\nRisk reduction observed against severe flare-ups of chronic obstructive pulmonary disease (COPD) and asthma<sup>\u20202<\/sup> during RSV-related hospitalization<\/p>\n<\/li>\n<\/ul>\n<p>PHILADELPHIA&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nGSK plc (LSE\/NYSE: GSK) today announced new effectiveness data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) at RSVVW\u201926, the 9th Conference of the Respiratory Syncytial Virus Foundation (ReSViNET) in Rome, Italy. GSK is presenting 19 abstracts at the congress and supporting a further 3, reflecting GSK\u2019s leadership in research and prevention of RSV. AREXVY is indicated for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 60 years of age and older, as well as individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.<\/p>\n<p>\nHospitalization places a significant burden on patients and health systems, particularly in winter months.<sup>3,4<\/sup> A retrospective cohort study was undertaken in the US with the primary objective to assess the effectiveness of GSK\u2019s RSV vaccine in helping to prevent RSV-related hospitalization in adults aged \u226560 years. It included over 2.5 million people, of which 520,440 were vaccinated individuals who were exact matched 1:4 to 2,081,760 unvaccinated individuals.<sup>1,2<\/sup> The vaccinated group received vaccination between August 1, 2023, and May 31, 2024, and the study observed risk reductions in this season.<\/p>\n<p>\nFor GSK\u2019s RSV vaccine, the study showed an association with 75.6% vaccine effectiveness (VE) against RSV-related hospitalization at a median follow-up of 5.6 months (maximum 9.7 months) post-vaccination (unvaccinated group, n=1,419\/2,081,760; vaccinated group, n=95\/520,440; 95% confidence interval: 69.8\u201380.2%).<sup>1,5<\/sup><\/p>\n<p>\nFurther exploratory endpoints showed an association with 63.1% VE against major adverse cardiovascular events (MACE), including heart attack and stroke, during RSV-related hospitalization among adults aged \u226560 years,<sup>\u20212,5<\/sup> (unvaccinated group, n=212\/699,177; vaccinated group, n=21\/170,803; 95% confidence interval: 41.8\u201376.6%). They also showed an association with 74.4% and 61.6% VE against severe COPD and asthma flare-ups, respectively, during RSV-related hospitalization among adults aged \u226560 years<sup>\u20202,5 <\/sup>(COPD unvaccinated group, n=265\/286,406; vaccinated group, n=20\/76,209; 95% confidence interval: 59.3\u201383.9%. Asthma unvaccinated group, n=57\/190,590; vaccinated group, n=7\/53,636; 95% confidence interval: 9.1\u201383.7%).<\/p>\n<p>\nIn a separate nationwide cohort study conducted in Denmark in COPD patients aged \u226560 years,<sup>\u2260<\/sup> it was observed that GSK\u2019s RSV vaccine was associated with VE of 100% in preventing RSV-related hospitalizations (unvaccinated group, n=115\/89,376; vaccinated group, n=0\/7448; 95% confidence interval: 71.1\u2013100%).<sup>6<\/sup><\/p>\n<p>\nAnalyses from both the US and Denmark studies will be presented at RSVVW\u201926.<\/p>\n<p>\nWhile observational research cannot demonstrate a causal association between RSV vaccination and reduced RSV-related risks, these findings add to a growing body of evidence of observed risk reductions in cardiovascular and respiratory underlying diseases. GSK\u2019s RSV vaccine is indicated for the prevention of RSV-lower respiratory tract disease (LRTD).<\/p>\n<p><b>Deepak L. Bhatt, MD, MPH, MBA, Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai in New York,<\/b> said: \u201cIn the real-world data being presented at RSVVW\u201926, it is observed that RSV vaccination could help reduce the risk of certain serious RSV-related outcomes, potentially including major adverse cardiovascular events such as heart attack and stroke, as well as severe flare-ups of COPD and asthma. These new data are a significant step in our understanding of how to help prevent such RSV-related health outcomes. I look forward to more data investigating this association further.\u201d<\/p>\n<p><b>Christian Felter, GSK Global Medical Lead, RSV,<\/b> said: \u201cThese data underscore the value of our RSV vaccine in its observed association with helping to prevent RSV-related hospitalization and reducing the risk of acute events of certain chronic conditions associated with this potentially serious disease. We are proud of our contribution at the forefront of generating innovative research in RSV to inform the clinical community and improve outcomes for patients.\u201d<\/p>\n<p><b>Notes:<br \/>\n<br \/><\/b>* Major adverse cardiovascular events (MACE) were defined in this analysis as: myocardial infarction, ischemic stroke, heart failure-related hospitalization, or unstable angina-related hospitalization.<br \/>\n<br \/>\u01c2 among US adults aged 60 years and older with existing cardiovascular disease (CVD)<br \/>\n<br \/>\u2020 among US adults aged 60 years and older with existing chronic obstructive pulmonary disease (COPD) and asthma, respectively<br \/>\n<br \/>\u2248 Dr. Bhatt is a paid consultant to GSK, who sponsored this study, and a co-author of a related study (#482 below).<br \/>\n<br \/>\u2260 among Danish adults aged 60 years and older with existing chronic obstructive pulmonary disease (COPD)<\/p>\n<p><b>Full list of GSK\u2019s presentations at RSVVW\u201926<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><b>Abstract name<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>Presenter<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwwidth7\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>Presentation details<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\" class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>RSV-related health outcomes and real-world evidence in older adults (\u226560 years) <\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nAdjuvanted RSVPreF3 vaccine effectiveness against RSV-related hospitalisation among US adults aged 60 years and older<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nElizabeth La<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth7 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n#429<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nEffectiveness of adjuvanted RSVPreF3 vaccine in preventing major adverse cardiovascular events, severe asthma exacerbations, and severe chronic obstructive pulmonary disease (COPD) exacerbations among US adults aged 60 years and older<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nElizabeth La<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth7 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n#428<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nReal-world evidence of the adjuvanted RSVPreF3 vaccine\u2019s uptake and effectiveness among Chronic Obstructive Pulmonary Disease patients in Denmark: A nationwide cohort study<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nMaria Jo\u00e3o Fonseca<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth7 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n#244<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nPublic Health Impact of Adjuvanted RSVPreF3 Vaccination in Adults Aged 60+ Years in four major metropolitan areas of China: Beijing, Chengdu, Guangzhou and Shanghai<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nEleftherios Zarkadoulas<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth7 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n#439<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nBeyond the acute episode: persistent functional and emotional burden after RSV hospitalisation in adults \u226565 years<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nAlejandro Orrico-S\u00e1nchez<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth7 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n#403<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\" class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>Protecting adults aged \u226518 years AIR for severe RSV disease<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nRisk of major adverse cardiovascular events after severe respiratory syncytial virus (RSV) disease among adults in the United States<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nElizabeth La<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth7 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n#482<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nAdjuvanted RSVPreF3 is non-inferior in adults 18\u201349 years of age (YOA) at increased risk for RSV disease compared to older adults \u226560 YOA: a post-hoc analysis by baseline medical condition<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nVeronica Hulstr\u00f8m<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth7 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n#310<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nCost-Effectiveness of the Adjuvanted RSV Prefusion F Vaccine in Adults 50\u201359 at Increased Risk in Italy<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nEleftherios Zarkadoulas<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth7 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n#381<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nBurden of RSV infection among hospitalised adults aged \u226550 years with acute respiratory infection in T\u00fcrkiye: a prospective, multicentre study<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nAdriana<br \/>\n<br \/>Guzman-Holst<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth7 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n#374<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nValuating RSV-related health states for younger adults and their caregivers in the United States \u2013 a time trade-off and sleep trade-off study<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nMaria Jo\u00e3o Fonseca<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth7 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n#235<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nProductivity and time loss estimates for adults with respiratory syncytial virus (RSV) disease and their caregivers in the United States (US) and Germany: a targeted literature review<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nMaria Waize<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth7 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n#284<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nSerious adverse events and potential immune-mediated diseases following one dose of adjuvanted RSVPreF3 in adults aged \u226518 years: pooled safety analysis from five clinical trials<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nVeronica Hulstr\u00f8m<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth7 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n#461<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\" class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>Societal impact of RSV vaccination<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nThe Hospital Burden of Disease, Mortality and Cost of Respiratory Syncytial Virus (RSV) in Queensland, Australia, 2024\u20132025<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nKrispin Hajkowicz<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth7 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n#356<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nHumanistic burden of respiratory syncytial virus disease in immunocompromised and high-risk adults in Germany and the United States: A cross-sectional concept elicitation study<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nAdriana<br \/>\n<br \/>Guzman-Holst<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth7 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n#291<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nModeled impact of racial and ethnic disparities in RSV vaccination uptake on RSV disease burden averted among US adults aged \u226560 years.<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nElizabeth La<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth7 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n#418<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nRespiratory Syncytial Virus Hospitalizations Among Adults in Thailand: A Nationwide Retrospective Observational Study (RSV-HAT)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nChadakan Yan<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth7 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n#308<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nRSV-related knowledge and practices among US adults at increased risk of severe RSV disease<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nElizabeth La<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth7 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n#415<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nUnlocking the value of RSV adult vaccination with adjuvanted RSVPreF3 Vaccine in Italy: A return on investment analysis using an integrated actuarial-macroeconomic model<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nEleftherios Zarkadoulas<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth7 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n#243<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nReducing the Burden on the Healthcare System Through the Introduction of RSV Vaccination in Germany<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nMaria Waize<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth7 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n#365<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nFrom value to equity: a distributional return of investment approach of RSV vaccination with RSVPreF3 OA in Spain with an actuarial and macroeconomic model<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nEleftherios Zarkadoulas<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth7 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n#481<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\" class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>Others<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nHigh-content spectral flow cytometric profiling of RSV-PreF3 and RSV-PostF\u2013specific B cells after AS01<sub>E<\/sub>-adjuvanted or unadjuvanted RSVPreF3 vaccination<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nStephane Guillaume<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth7 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n#286<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth81 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nEstablishing a Controlled Human Infection Model with a contemporary Respiratory Syncytial Virus B challenge agent in healthy volunteers<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth12 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nIngrid M.C. de Visser \u2013 Kamerling<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwwidth7 bwvertalignm\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n#283<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p><b>About the US real-world evidence study<br \/>\n<br \/><\/b>The two abstracts presented report findings from a retrospective cohort study conducted using US administrative claims data from the Optum Research Database (ORD; August 2022\u2013May 2024).<sup>1,2<\/sup> The first abstract evaluates VE against RSV-related hospitalization (defined by International Classification of Diseases, Tenth Revision, Clinical Modification diagnosis codes for RSV).<sup>2<\/sup> The second abstract estimates VE of GSK\u2019s RSV vaccine against MACE, and against severe flare-ups of COPD and asthma.<sup>1<\/sup> A total of 520,440 vaccinated and 2,081,760 unvaccinated individuals were included in the overall study.<sup>1,2 <\/sup>The analyses included adults aged \u226560 years identified between August 2023\u2013May 2024.<sup>1,2<\/sup><\/p>\n<p><b>About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted)<br \/>\n<br \/><\/b>AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK\u2019s proprietary AS01<sub>E<\/sub> adjuvant before administration.<\/p>\n<p>\nThe use of this vaccine should be in accordance with official recommendations. As with any vaccine, a protective immune response may not be elicited in all vaccinees.<\/p>\n<p>\nThe vaccine has been approved for the prevention of RSV-lower respiratory tract disease (LRTD) in individuals 60 years of age and older in more than 65 countries. In addition, it is approved for use in individuals aged 50-59 who are at increased risk due to certain underlying medical conditions in more than 55 countries, including the US and Japan. In the European Economic Area, it is approved for use in adults aged 18 years and older. Please refer to the Product Information (PI) for important dosage, administration, and safety information in Europe at this link: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ema.europa.eu%2Fmedicines%2Fhuman%2FEPAR%2Farexvy&amp;esheet=54427570&amp;newsitemid=20260217706893&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.ema.europa.eu%2Fmedicines%2Fhuman%2F%2FEPAR%2Farexvy&amp;index=1&amp;md5=1fe8803ac1df6d22b3e24562f7dd37f7\">http:\/\/www.ema.europa.eu\/medicines\/human\/\/EPAR\/arexvy<\/a> and in the US at this link: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fgskpro.com%2Fcontent%2Fdam%2Fglobal%2Fhcpportal%2Fen_US%2FPrescribing_Information%2FArexvy%2Fpdf%2FAREXVY.PDF&amp;esheet=54427570&amp;newsitemid=20260217706893&amp;lan=en-US&amp;anchor=https%3A%2F%2Fgskpro.com%2Fcontent%2Fdam%2Fglobal%2Fhcpportal%2Fen_US%2FPrescribing_Information%2FArexvy%2Fpdf%2FAREXVY.PDF&amp;index=2&amp;md5=3286d7d94f6abd0a2ad81058388ba69d\">https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Arexvy\/pdf\/AREXVY.PDF<\/a><\/p>\n<p>\nThe GSK proprietary AS01 adjuvant system contains STIMULON QS-21 adjuvant licensed from Antigenics LLC, a wholly owned subsidiary of Agenus Inc. STIMULON is a trademark of SaponiQx Inc., a subsidiary of Agenus.<\/p>\n<p><b>Indication for AREXVY<br \/>\n<br \/><\/b>AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIndividuals 60 years of age and older;<\/p>\n<\/li>\n<li>\nIndividuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.<\/p>\n<\/li>\n<\/ul>\n<p><b>Important Safety Information for AREXVY<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nAREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY<\/p>\n<\/li>\n<li>\nThe results of a postmarketing observational study suggest an increased risk of Guillain-Barr\u00e9 syndrome during the 42 days following vaccination with AREXVY<\/p>\n<\/li>\n<li>\nAppropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of AREXVY<\/p>\n<\/li>\n<li>\nSyncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting<\/p>\n<\/li>\n<li>\nImmunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY\u200b<\/p>\n<\/li>\n<li>\nIn adults 60 years of age and older, the most commonly reported adverse reactions (\u226510%) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)<\/p>\n<\/li>\n<li>\nIn adults 50 through 59 years of age, the most commonly reported adverse reactions (\u226510%) were injection site pain (75.8%), fatigue (39.8%), myalgia (35.6%), headache (31.7%), arthralgia (23.4%), erythema (13.2%), and swelling (10.4%)<\/p>\n<\/li>\n<li>\nThere are no data on the use of AREXVY in pregnant or breastfeeding individuals. AREXVY is not approved for use in persons &lt;50 years of age<\/p>\n<\/li>\n<li>\nVaccination with AREXVY may not result in protection of all vaccine recipients<\/p>\n<\/li>\n<\/ul>\n<p>\nPlease see full <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fgskpro.com%2Fcontent%2Fdam%2Fglobal%2Fhcpportal%2Fen_US%2FPrescribing_Information%2FArexvy%2Fpdf%2FAREXVY.PDF&amp;esheet=54427570&amp;newsitemid=20260217706893&amp;lan=en-US&amp;anchor=Prescribing+Information&amp;index=3&amp;md5=9c7341225df8d81f00e3b4f61d7b7121\">Prescribing Information<\/a> for AREXVY.<\/p>\n<p><b>About RSV in adults<br \/>\n<br \/><\/b>RSV is a common contagious virus affecting the lungs and breathing passages and impacts an estimated 64 million people of all ages globally every year.<sup>7<\/sup> Adults can be at increased risk for severe RSV disease due to certain comorbidities including COPD, asthma, and chronic heart failure, immunocompromised status, or advanced age.<sup>8<\/sup> In the US, it is estimated that there are between 6,000 and 10,000 RSV-related deaths annually in older adults and between 110,000 and 180,000 hospitalizations in people aged 50 and over.<sup>9,10<\/sup> RSV can exacerbate certain medical conditions, and lead to severe illness resulting in hospitalization and even death.<sup>8,11,12<\/sup> Compared to children, adults hospitalized for RSV are at a higher risk of severe complications, require more costly treatments, have a higher fatality rate, and the true number of RSV-related cases is likely underestimated due to lack of routine testing.<sup>13,14,15,16<\/sup><\/p>\n<p><b>About GSK<br \/>\n<br \/><\/b>GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gsk.com&amp;esheet=54427570&amp;newsitemid=20260217706893&amp;lan=en-US&amp;anchor=www.gsk.com&amp;index=4&amp;md5=50a8f4ee806b78fa03088f8f6b137586\">www.gsk.com<\/a>.<\/p>\n<p><b>Cautionary statement regarding forward-looking statements<br \/>\n<br \/><\/b>GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the \u201cRisk Factors\u201d section in GSK\u2019s Annual Report on Form 20-F for 2024, and GSK\u2019s Q4 Results for 2025.<\/p>\n<p><b>Registered in England &amp; Wales:<br \/>\n<br \/><\/b>No. 3888792<\/p>\n<p><b>Registered Office:<br \/>\n<br \/><\/b>79 New Oxford Street<br \/>\n<br \/>London<br \/>\n<br \/>WC1A 1DG<\/p>\n<p><b>References:<\/b><\/p>\n<p><sup>1<\/sup> Singer D, et al. Adjuvanted RSVPreF3 vaccine effectiveness against RSV-related hospitalization among US adults aged 60 years and older. Abstract presented at Respiratory Syncytial Virus network (ReSViNET) 2026 Congress; 17\u201320 February, Rome, Italy<br \/>\n<br \/><sup>2<\/sup> Singer D, et al. Effectiveness of adjuvanted RSVPreF3 vaccine in preventing major adverse cardiovascular events, severe asthma exacerbations, and severe COPD exacerbations among US adults aged 60 years and older. Abstract presented at Respiratory Syncytial Virus network (ReSViNET) 2026 Congress; 17\u201320 February, Rome, Italy<br \/>\n<br \/><sup>3<\/sup> European Centre for Disease Prevention and Control. Acute respiratory infections in the EU\/EEA: epidemiological update and current public health recommendations \u2013 winter 2024\/2025. Available at: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ecdc.europa.eu%2Fen%2Fnews-events%2Facute-respiratory-infections-eueea-epidemiological-update-and-current-public-health-0&amp;esheet=54427570&amp;newsitemid=20260217706893&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.ecdc.europa.eu%2Fen%2Fnews-events%2Facute-respiratory-infections-eueea-epidemiological-update-and-current-public-health-0&amp;index=5&amp;md5=18ff370f838225a36a026b8d6dbfa320\">https:\/\/www.ecdc.europa.eu\/en\/news-events\/acute-respiratory-infections-eueea-epidemiological-update-and-current-public-health-0<\/a>. Last accessed: February 2026<br \/>\n<br \/><sup>4<\/sup> Savi\u0107, M., Penders, Y., Shi, T., Campbell, H., &amp; Nair, H. (2023). Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: A systematic literature review and meta-analysis. Influenza and Other Respiratory Viruses, 17(1), e13031. <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdoi.org%2F10.1111%2Firv.13031&amp;esheet=54427570&amp;newsitemid=20260217706893&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdoi.org%2F10.1111%2Firv.13031&amp;index=6&amp;md5=8a9a73acd05183bd25eff6b13fd516ef\">https:\/\/doi.org\/10.1111\/irv.13031<br \/>\n<\/a><br \/><sup>5<\/sup> GSK. Data on file, 2024N560279.<br \/>\n<br \/><sup>6<\/sup> Fonseca M, et al. Real-World Evidence of the Adjuvanted-RSVPreF3 Vaccine\u2019s Uptake and Effectiveness among Chronic Obstructive Pulmonary Disease Patients in Denmark: A Nationwide Cohort Study. Abstract presented at Respiratory Syncytial Virus network (ReSViNET) 2026 Congress; 17\u201320 February, Rome, Italy<br \/>\n<br \/><sup>7<\/sup> National Institute of Allergy and Infectious Diseases, Respiratory Syncytial Virus (RSV). Available at: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niaid.nih.gov%2Fdiseases-conditions%2Frespiratory-syncytial-virus-rsv&amp;esheet=54427570&amp;newsitemid=20260217706893&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.niaid.nih.gov%2Fdiseases-conditions%2Frespiratory-syncytial-virus-rsv&amp;index=7&amp;md5=19b230cccf0a515f21a4946b55d13653\">https:\/\/www.niaid.nih.gov\/diseases-conditions\/respiratory-syncytial-virus-rsv<\/a>. Last accessed: February 2026<br \/>\n<br \/><sup>8<\/sup> Atamna A, et al. Morbidity and mortality of respiratory syncytial virus infection in hospitalized adults: Comparison with seasonal influenza. Int J Infect Dis. 2021 Feb:103:489-493. doi: 10.1016\/j.ijid.2020.11.185<br \/>\n<br \/><sup>9<\/sup> Kim T &amp; Choi SH. Epidemiology and Disease Burden of Respiratory Syncytial Virus Infection in Adults. Infect Chemother. 2024 Mar;56(1):1-12. doi: 10.3947\/ic.2024.0011. Epub 2024 Mar 12. PMID: 38527779; PMCID: PMC10990889.<br \/>\n<br \/><sup>10<\/sup> Centers for Disease Control and Prevention. Respiratory Syncytial Virus Infection (RSV). Available at: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cdc.gov%2Frsv%2Fadults%2Findex.html&amp;esheet=54427570&amp;newsitemid=20260217706893&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.cdc.gov%2Frsv%2Fadults%2Findex.html&amp;index=8&amp;md5=858bad058544fdba7eedbc7d7449c645\">https:\/\/www.cdc.gov\/rsv\/adults\/index.html<\/a>. Last accessed: February 2026<br \/>\n<br \/><sup>11<\/sup>Osei-Yeboah R, et al. Estimation of the Number of Respiratory Syncytial Virus\u2013Associated Hospitalizations in Adults in the European Union. <i>J Infect Dis <\/i>2023 May 29;228(11):1539\u20131548. doi: 10.1093\/infdis\/jiad189<br \/>\n<br \/><sup>12<\/sup> Falsey, AR et al. Respiratory syncytial virus infection in elderly and high-risk adults, in <i>New Engl J Med <\/i>2005; 352:1749-59. doi: 10.1056\/NEJMoa043951<br \/>\n<br \/><sup>13<\/sup> Niekler, P, et al. Hospitalizations due to respiratory syncytial virus (RSV) infections in Germany: a nationwide clinical and direct cost data analysis (2010-2019). <i>Infection<\/i>. 2024 Oct;52(5):1715-1724. doi: 10.1007\/s15010-023-02122-8<br \/>\n<br \/><sup>14<\/sup> G\u00fcnen H, et al. Key Challenges to Understanding the Burden of Respiratory Syncytial Virus in Older Adults in Southeast Asia, the Middle East, and North Africa: An Expert Perspective.<i> Adv Ther.<\/i> 2024 Nov;41(11):4312-4334. <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdoi.org%2F10.1007%2Fs12325-024-02954-2&amp;esheet=54427570&amp;newsitemid=20260217706893&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdoi.org%2F10.1007%2Fs12325-024-02954-2&amp;index=9&amp;md5=911e233a914286df160bfe48020c7493\">https:\/\/doi.org\/10.1007\/s12325-024-02954-2<br \/>\n<\/a><br \/><sup>15<\/sup> Alfano, F., Bigoni, T., Caggiano, F.P. et al. Respiratory Syncytial Virus Infection in Older Adults: An Update. <i>Drugs Aging <\/i>41, 487\u2013505 (2024). <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdoi.org%2F10.1007%2Fs40266-024-01118-9&amp;esheet=54427570&amp;newsitemid=20260217706893&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdoi.org%2F10.1007%2Fs40266-024-01118-9&amp;index=10&amp;md5=3c3d0c61aedd06db9060879414a6ffa1\">https:\/\/doi.org\/10.1007\/s40266-024-01118-9<br \/>\n<\/a><br \/><sup>16<\/sup> Grace, M., Colosia, A., Wolowacz, S., Panozzo, C., &amp; Ghaswalla, P. (2023). Economic burden of respiratory syncytial virus infection in adults: a systematic literature review. <i>Journal of Medical Economics<\/i>, <i>26<\/i>(1), 742\u2013759. <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdoi.org%2F10.1080%2F13696998.2023.2213125&amp;esheet=54427570&amp;newsitemid=20260217706893&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdoi.org%2F10.1080%2F13696998.2023.2213125&amp;index=11&amp;md5=974388a9718c50124fa09c2618253357\">https:\/\/doi.org\/10.1080\/13696998.2023.2213125<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260217706893r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260217706893\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260217706893\/en\/<\/a><\/span><\/p>\n<p><b>GSK inquiries <\/b><\/p>\n<p>\nMedia:<\/p>\n<p>\nTim Foley +44 (0) 20 8047 5502 (London)<br \/>\n<br \/>Simon Moore +44 (0) 20 8047 5502 (London)<br \/>\n<br \/>Alison Hunt +1 540 742 3391 (Washington DC)<\/p>\n<p>\nInvestor Relations:<\/p>\n<p>\nConstantin Fest +44 (0) 7831 826525 (London)<br \/>\n<br \/>James Dodwell +44 (0) 20 8047 2406 (London)<br \/>\n<br \/>Mick Readey +44 (0) 7990 339653 (London)<br \/>\n<br \/>Steph Mountifield +44 (0) 7796 707505 (London)<br \/>\n<br \/>Sam Piper +44 (0) 7824 525779 (London)<br \/>\n<br \/>Jeff McLaughlin +1 215 751 7002 (Philadelphia)<br \/>\n<br \/>Frannie DeFranco +1 215 751 3126 (Philadelphia)<\/p>\n<p><b>KEYWORDS:<\/b> Pennsylvania Europe United States Italy North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Biotechnology Research Pharmaceutical Health FDA Infectious Diseases Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260217706893\/en\/2146668\/3\/GSK_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>GSK\u2019s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows Reduction observed in RSV-related hospitalizations in adults aged \u226560 years1 An observed reduction in major adverse cardiovascular events* in adults aged \u226560 years\u01c22 during RSV-related hospitalization Risk reduction observed against severe flare-ups of chronic obstructive pulmonary disease (COPD) and asthma\u20202 during RSV-related hospitalization PHILADELPHIA&#8211;(BUSINESS WIRE)&#8211; GSK plc (LSE\/NYSE: GSK) today announced new effectiveness data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) at RSVVW\u201926, the 9th Conference of the Respiratory Syncytial Virus Foundation (ReSViNET) in Rome, Italy. GSK is presenting 19 abstracts at the congress and supporting a further 3, reflecting GSK\u2019s leadership in research and prevention &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;GSK\u2019s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-937797","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GSK\u2019s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK\u2019s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GSK\u2019s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows Reduction observed in RSV-related hospitalizations in adults aged \u226560 years1 An observed reduction in major adverse cardiovascular events* in adults aged \u226560 years\u01c22 during RSV-related hospitalization Risk reduction observed against severe flare-ups of chronic obstructive pulmonary disease (COPD) and asthma\u20202 during RSV-related hospitalization PHILADELPHIA&#8211;(BUSINESS WIRE)&#8211; GSK plc (LSE\/NYSE: GSK) today announced new effectiveness data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) at RSVVW\u201926, the 9th Conference of the Respiratory Syncytial Virus Foundation (ReSViNET) in Rome, Italy. GSK is presenting 19 abstracts at the congress and supporting a further 3, reflecting GSK\u2019s leadership in research and prevention &hellip; Continue reading &quot;GSK\u2019s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-18T13:14:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260217706893r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"GSK\u2019s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows\",\"datePublished\":\"2026-02-18T13:14:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\\\/\"},\"wordCount\":2621,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260217706893r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\\\/\",\"name\":\"GSK\u2019s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260217706893r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-02-18T13:14:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260217706893r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260217706893r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK\u2019s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GSK\u2019s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\/","og_locale":"en_US","og_type":"article","og_title":"GSK\u2019s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows - Market Newsdesk","og_description":"GSK\u2019s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows Reduction observed in RSV-related hospitalizations in adults aged \u226560 years1 An observed reduction in major adverse cardiovascular events* in adults aged \u226560 years\u01c22 during RSV-related hospitalization Risk reduction observed against severe flare-ups of chronic obstructive pulmonary disease (COPD) and asthma\u20202 during RSV-related hospitalization PHILADELPHIA&#8211;(BUSINESS WIRE)&#8211; GSK plc (LSE\/NYSE: GSK) today announced new effectiveness data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) at RSVVW\u201926, the 9th Conference of the Respiratory Syncytial Virus Foundation (ReSViNET) in Rome, Italy. GSK is presenting 19 abstracts at the congress and supporting a further 3, reflecting GSK\u2019s leadership in research and prevention &hellip; Continue reading \"GSK\u2019s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-18T13:14:59+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260217706893r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"GSK\u2019s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows","datePublished":"2026-02-18T13:14:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\/"},"wordCount":2621,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260217706893r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\/","name":"GSK\u2019s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260217706893r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-02-18T13:14:59+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260217706893r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260217706893r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gsks-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"GSK\u2019s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=937797"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937797\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=937797"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=937797"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=937797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}